Jubilant Pharmova Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #72 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Jubilant Pharmova Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
How did Jubilant Pharmova's revenue grow in the September 2026 quarter?
See what Jubilant Pharmova Ltd said on revenue & sales performance — free account, 30 seconds.
What happened to Jubilant Pharmova's margins in Q2 FY27?
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
What capex is Jubilant Pharmova planning?
See what Jubilant Pharmova Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Jubilant Pharmova raising money or cutting debt?
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Jubilant Pharmova's order book?
See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹2.2K Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Viyash Scientific (Q2 FY27)
Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8) . Key investor presentation takeaways from Viyash Scientific Ltd's Q2 FY27 investor prese
- Natco Pharma (Q2 FY27)
EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline) . Key investor presentation takeaways from Natco Pharma Ltd's Q2 FY27 invest
- Vineet Laborator (Q2 FY27)
Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27
- Balaxi Pharma (Q2 FY27)
34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹15,405 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.